Plasma-derived therapies — immunoglobulins, albumin, clotting factors, and alpha-1 antitrypsin — represent one of the most operationally complex and commercially defensible segments of the biopharmaceutical industry. CSL Behring is the world leader in plasma-derived therapies, with a plasma collection network spanning over 300 collection centers globally and annual revenue from plasma-derived products exceeding $10 billion. The industry is protected by substantial barriers to entry — the plasma collection infrastructure, fractionation manufacturing assets, and regulatory approval requirements create a consolidated competitive landscape dominated by CSL, Takeda (via Shire's Baxalta), Grifols, and Octapharma.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Plasma-Derived Therapy Market
• Immunoglobulin Market Dynamics
• CSL Behring Competitive Leadership
• Plasma Collection Infrastructure
• Fractionation Manufacturing
• Recombinant Factor Replacement
• Subcutaneous Immunoglobulin
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. Plasma-Derived Therapy Market
4. Immunoglobulin Market Dynamics
5. CSL Behring Competitive Leadership
6. Plasma Collection Infrastructure
7. Fractionation Manufacturing
8. Recombinant Factor Replacement
9. Subcutaneous Immunoglobulin
10. Competitive Landscape
11. Competitive Landscape
12. Regional Market Analysis
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Pipeline Assessment 2025
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Amgen
Gilead Sciences
Regeneron
Biogen
Vertex
BioNTech
Moderna
Genentech
CSL Behring
